Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Liping Lan
Institution:
Shanghai AbelZeta Ltd. (China)
Observed institutions:
Sun Yat-sen University,
Sun Yat-sen Memorial Hospital,
Cellular Biomedicine Group (United States),
Shanghai AbelZeta Ltd. (China)
ORCID:
0000-0002-6093-1443
Observed ORCID:
0000-0002-6093-1443
OpenAlex ID:
A5110716579
Alterations of brain activity and functional connectivity in transition from acute to chronic tinnitus
2020
·
Liping Lan
, Jiahong Li
, et al.
·
Human Brain Mapping
·
44
PDF
Investigating the use of a two-stage attention-aware convolutional neural network for the automated diagnosis of otitis media from tympanic membrane images: a prediction model development and validation study
2021
·
Yuexin Cai
, Jin-Gang Yu
, et al.
·
BMJ Open
·
42
PDF
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
2022
·
Xiaoyan Qu
, Gang An
, et al.
·
Journal for ImmunoTherapy of Cancer
·
34
PDF
Aberrant Functional and Causal Connectivity in Acute Tinnitus With Sensorineural Hearing Loss
2020
·
Yuexin Cai
, Mingwei Xie
, et al.
·
Frontiers in Neuroscience
·
32
PDF
Topological features of limbic dysfunction in chronicity of tinnitus with intact hearing: New hypothesis for ‘noise-cancellation’ mechanism
2021
·
Liping Lan
, Yu-Chen Chen
, et al.
·
Progress in Neuro-Psychopharmacology and Biological Psychiatry
·
29
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
2025
·
Wenjuan Yu
, Ping Li
, et al.
·
Blood
·
28
PDF
Specific brain network predictors of interventions with different mechanisms for tinnitus patients
2022
·
Liping Lan
, Yin Liu
, et al.
·
EBioMedicine
·
25
Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
2021
·
Aibin Liang
, Shiguang Ye
, et al.
·
Journal of Clinical Oncology
·
22
An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
2020
·
Gang An
, Weiwei Sui
, et al.
·
Blood
·
22
C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
2023
·
Ping Li
, Wen-Juan Yu
, et al.
·
Blood
·
20
Cross-Subject Tinnitus Diagnosis Based on Multi-Band EEG Contrastive Representation Learning
2023
·
Chang-Dong Wang
, Xi-Ran Zhu
, et al.
·
IEEE Journal of Biomedical and Health Informatics
·
19
PDF
Efficacy of Tailor-Made Notched Music Training Versus Tinnitus Retraining Therapy in Adults With Chronic Subjective Tinnitus: A Randomized Controlled Clinical Trial
2022
·
Zhaopeng Tong
, Wenting Deng
, et al.
·
Ear and Hearing
·
19
Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
2019
·
Xin Yao
, Shigui Zhu
, et al.
·
Blood
·
10
Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
2021
·
Aibin Liang
, Lili Zhou
, et al.
·
Journal of Clinical Oncology
·
5
Expert recommendations on collection and annotation of otoscopy images for intelligent medicine
2022
·
Yuexin Cai
, Junbo Zeng
, et al.
·
Intelligent Medicine
·
4
PDF
Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
2021
·
Xiaoyan Qu
, Gang An
, et al.
·
Blood
·
4
Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy
2020
·
Shiguang Ye
, Jiaqi Huang
, et al.
·
Blood
·
4
Aberrant Modulations of Neurocognitive Network Dynamics in Migraine Comorbid With Tinnitus
2022
·
Liping Lan
, Yin Liu
, et al.
·
Frontiers in Aging Neuroscience
·
3
PDF
A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
2024
·
Gang An
, Yan Xu
, et al.
·
Blood
·
2
Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients
2024
·
Yan Xu
, Wensi Li
, et al.
·
Blood
·
2
Reduced Functional Connectivity in Children With Congenital Cataracts Using Resting-State Electroencephalography Measurement
2021
·
Wan Chen
, Liping Lan
, et al.
·
Frontiers in Neuroscience
·
2
PDF
Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy
2023
·
Yan Xu
, Wensi Li
, et al.
·
Blood
·
1
PDF
Phase 1/2 study of Trovocabtagene autoleucel, a BCMA CART, combined with ASCT in UHR MM and pPCL
2026
·
Yan Xu
, Wensi Li
, et al.
·
Research Square
PDF
Self-Reported Hearing Impairment And Risk of Mental Disorders: A Two-Sample Mendelian Randomization Study
2023
·
Qianhui Xu
, Junbo Zeng
, et al.
·
SSRN Electronic Journal
Tinnitus Affects Endogenous But Not Exogenous Auditory Attention Orienting
2022
·
Yichen Yuan
, Yuexin Cai
, et al.
·
American Journal of Audiology
Show more works
View as search
Works count:
29
Citation count:
373
H-index:
12
I10-index:
13
Year
Topic
Type